Full-Time
Quality Control Associate 1
Posted on 9/16/2025
Parse Biosciences
51-200 employees
Provides single-cell analysis kits and software
Compensation Overview
$26.44 - $34.62/hr
Seattle, WA, USA
In Person
 Biology & Biotech (2) |
|---|
| , |
- A Bachelor’s degree in Molecular Biology, Biochemistry, or related biological sciences.
- A minimum of 6 months of professional experience performing molecular biology techniques such as PCR, ELISA, DNA/RNA extractions, bead cleanups, cell counting and quantification assays.
- Execute Parse’s Evercode fixation, whole transcriptome, and immune profiling protocols using established analytical chemistry and genomics techniques such as pipetting, PCR, ELISA, DNA/RNA extraction, bead cleanup, cell counting, quantification, and next-generation sequencing (NGS).
- Follow all established policies, procedures, and practices, including Parse’s safety requirements, Parse’s Quality System, Good Documentation Practices (GDP), Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), etc.
- Select, receive, and store QC aliquots in order to maintain chain of custody and to help process materials in a safe, compliant, and expeditious manner.
- Identify potential or suspected nonconformities to prevent unintended use or delivery of products, escalating issues to area management.
- Contribute to cross-functional Quality investigations and continuous improvement initiatives. Assist in root cause analyses (RCA) and implementation of proposed corrective and preventive actions (CAPA).
- Assist in writing and revising standard operating procedures, test methods, and batch records consistent with established document management guidelines.
- Participate in the review of test results and disposition of finished goods.
- Perform routine maintenance tasks including cleaning and calibrating equipment, culturing cells, creating inventory requisitions, and organizing inventory and freezers.
- NGS library preparation, single-cell library preparation, or experience in a medium to high volume GxP environment is preferred.
Parse Biosciences provides tools and software for single-cell analysis to genomics and molecular biology researchers. Their core offering centers on splitting cells into nuclei suspensions, labeling each cell with a unique barcode through split-pool combinatorial barcoding, and then sequencing and analyzing data. The end-to-end solution includes sample prep, sequencing, and data interpretation through their Trailmaker software, designed to work without expensive custom instruments. The company differentiates itself by delivering a scalable, kit-based workflow plus integrated software that allows researchers to perform high-throughput single-cell analysis in-house, reducing reliance on specialized equipment and outsourcing. The goal is to democratize access to advanced single-cell techniques, enabling more scientists and institutions to study biological systems and diseases at the single-cell level.
Company Size
51-200
Company Stage
Acquired
Total Funding
$324.7M
Headquarters
Seattle, Washington
Founded
2018
Simplify's Take
What believers are saying
- QIAGEN acquires Parse for $225 million upfront plus $55 million milestones, closing December 2025.
- Tahoe Therapeutics contracts GigaLab for 300 million single-cell profiles from perturbed models.
- Evercode v4 launches March 2026 with 75% higher cell recovery and magnetic bead workflow.
What critics are saying
- QIAGEN integration loses co-founders Rosenberg and Roco, slowing R&D in 12-24 months.
- 10X Genomics dominates with instrument lock-in, blocking Parse adoption in 18-36 months.
- AI models from Tahoe and Graph datasets cut GigaLab experiments by 40-60% in 24-36 months.
What makes Parse Biosciences unique
- Split-pool combinatorial barcoding eliminates microfluidic instruments for scalable single-cell sequencing.
- Evercode enables fixation, freezing, and batching samples from different dates in one experiment.
- GigaLab processes up to five million cells per run for massive AI-training datasets.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
Company Equity
Paid Holidays
Paid Vacation
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 0%Parse Biosciences, a QIAGEN company, has launched Evercode Whole Transcriptome FFPE kits, enabling whole transcriptome single-cell RNA sequencing from formalin-fixed, paraffin-embedded samples for the first time. The technology addresses a major limitation in accessing FFPE samples, which represent the world's largest repository of clinically annotated tissue. Previously, RNA degradation in FFPE samples forced researchers to rely on predefined gene panels, limiting full transcriptome analysis. Parse's solution uses a novel split-pool combinatorial barcoding approach and proprietary reverse transcription-based RNA capture chemistry designed for compromised RNA. The technology allows cancer, neuroscience and translational researchers to access single-cell resolution across the full transcriptome for new and archived FFPE samples. The kits are now shipping to customers.
Maximize every sample: how Evercode v4 redefines performance in Whole Transcriptome profiling. Published: 24 Mar 2026 Parse Biosciences, a part of QIAGEN known as the leading provider of scalable and accessible single-cell sequencing solutions, has launched the new Evercode(TM) Whole Transcriptome v4 product line today. This new product improves scalability, boosts sensitivity, and streamlines the workflow for single-cell RNA sequencing. Precision at scale: Parse Biosciences unveils v4 chemistry with unmatched gene sensitivity. The Evercode v4 system features impressive scalability, supporting up to five million cells and 384 samples in one run. This allows researchers to perform large studies while maintaining sample resolution. The enhanced chemistry improves gene detection per cell and reduces the number of sequencing reads needed, which helps lower overall sequencing costs. According to Precedence Research, the Specimen Retrieval Market size accounted for USD 316.22 billion in 2025 and is predicted to increase from USD 330.86 billion in 2026 to approximately USD 497.22 billion by 2035, expanding at a CAGR of 4.63% from 2026 to 2035 as demand grows for adoption of minimally invasive surgery, focus on patient safety and infection control and growing prevalence of chronic diseases. A new magnetic bead-based workflow has been introduced, replacing the traditional centrifugation steps and improving cell recovery by up to 75%. This innovation allows researchers to gather more data from limited or precious samples. The optimized process reduces hands-on time and the number of pipetting steps, and is designed to support laboratory automation, making it suitable for labs with different levels of experience in single-cell techniques. Capture every detail: enhanced Retrieval for rare cell discovery in Evercode v4. Additionally, Evercode v4 effectively removes off-target reads, which improves gene detection per cell, even at lower sequencing depths and costs compared to other options. With its high sensitivity, Evercode v4 offers better biological resolution for researchers studying rare cell types or genes with low expression levels. The chemistry behind Evercode Whole Transcriptome v4 is present across the entire Evercode Whole Transcriptome product range, which features Evercode Fixation and experiments carried out in Parse's GigaLab. "From the beginning, our goal has been to provide the research community with single-cell technology that is scalable, accessible, and high-performing," said Charlie Roco, PhD, Co-founder and Chief Technology Officer of Parse Biosciences. "Evercode v4 reflects years of development and direct feedback from its users, marking a major improvement in cell recovery and sensitivity, along with a simpler workflow. A recent report by Precedence Research highlights that the Specimen Retrieval Market is benefiting from technological advancements in robotic-assisted devices, growing demand for patient safety and infection control, and increasing healthcare infrastructure investments in emerging markets.
Parse Biosciences, a QIAGEN company, has launched Evercode Whole Transcriptome v4, an upgraded single-cell RNA sequencing platform offering enhanced scalability and performance. The new chemistry supports up to five million cells and 384 samples in a single run whilst increasing gene detection per cell with fewer sequencing reads. A new magnetic bead-based workflow replaces centrifugation steps, boosting cell recovery by up to 75% and reducing hands-on time. The system eliminates off-target reads, enabling higher gene detection at lower sequencing depths and costs. The streamlined process is designed to support laboratory automation, making it accessible to labs with varying experience levels. Evercode v4 is available across the entire Evercode Whole Transcriptome product line and is planned to begin shipping in March 2026.
Parse Biosciences launches Evercode Whole Transcriptome v4 with shorter workflow, higher sensitivity and higher cell recovery. New chemistry reduces barriers to scaling single-cell studies across research settings SEATTLE - February 19, 2026 - Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single cell sequencing solutions today announced the launch of the new Evercode(TM) Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity, and a simplified workflow for single cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to 5 million cells and 384 samples in a single run, enabling researchers to design large studies while maintaining sample resolution. The upgraded chemistry increases gene detection per cell while requiring fewer sequencing reads, helping reduce overall sequencing costs. A new magnetic bead-based workflow replaces centrifugation steps and increases cell recovery by up to 75%, allowing researchers to generate more data from limited or precious samples. The streamlined process reduces hands-on time and pipetting steps and is designed to support laboratory automation, making the system accessible to laboratories with varying levels of single-cell experience. Additionally, Evercode v4 eliminates off-target reads, enabling higher gene detection per cell even at lower sequencing depths and lower costs than other solutions. With higher sensitivity, Evercode v4 delivers higher biological resolution for researchers studying rare cell types or lowly expressed genes. Evercode Whole Transcriptome v4 chemistry is available across the Evercode Whole Transcriptome product line, including Evercode Fixation and experiments processed through Parse's GigaLab. "Our goal from the beginning was to provide the research community with single cell technology that is scalable, accessible, and high-performing," said Charlie Roco, PhD, Co-founder and Chief Technology Officer of Parse Biosciences. "Evercode v4 reflects years of work and direct feedback from customers, delivering a leap forward in cell recovery and sensitivity combined with a simpler workflow." Evercode Whole Transcriptome v4 is planned to begin shipping in March 2026. To learn more about the new chemistry, visit Parse at the upcoming AGBT meeting (Duval Room) or register for Parse's upcoming webinar on Tuesday, March 3, 2026 at 9:00 AM Pacific: https://resources.parsebiosciences.com/evercode-wt-v4. About Parse Biosciences Parse Biosciences, a QIAGEN Company, is a global life sciences leader whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Parse contact: Kaitie VanDenHeuvel-Kramer [email protected] +1 858-504-0455
Parse Biosciences has launched a fully integrated immune repertoire and transcriptome analysis workflow in its data analysis platform, Trailmaker. The new functionality addresses a longstanding gap in immunology research by connecting immune repertoire data with whole transcriptome single cell insights in a cohesive environment. The platform combines immune repertoire and whole transcriptome data, allowing researchers to visualise clonotypes and cell types, identify dominant clones, and detect conserved patterns through motif analysis. Users can link repertoire data with full transcriptome expression to reveal clonotype-specific gene programmes and run targeted differential expression. Previously, immunologists lacked an integrated platform for this type of analysis, often requiring fragmented tools and custom code. The new Trailmaker functionality provides an accessible end-to-end solution for immune profiling.